Nathalie Schwenk
Overview
Explore the profile of Nathalie Schwenk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urnauer S, Schmohl K, Tutter M, Schug C, Schwenk N, Morys S, et al.
Gene Ther
. 2024 Jul;
31(9-10):525-526.
PMID: 38992289
No abstract available.
2.
Spellerberg R, Benli-Hoppe T, Kitzberger C, Hageneier M, Schwenk N, Ozturk O, et al.
Mol Ther Oncolytics
. 2022 Dec;
27:272-287.
PMID: 36458201
Sodium iodide symporter () gene transfer for active accumulation of iodide in tumor cells is a powerful theranostic strategy facilitating both diagnostic and therapeutic application of radioiodide. In glioblastoma (GBM),...
3.
Kitzberger C, Spellerberg R, Morath V, Schwenk N, Schmohl K, Schug C, et al.
EJNMMI Res
. 2022 May;
12(1):25.
PMID: 35503582
Cloning of the sodium iodide symporter (NIS) in 1996 has provided an opportunity to use NIS as a powerful theranostic transgene. Novel gene therapy strategies rely on image-guided selective NIS...
4.
Spellerberg R, Benli-Hoppe T, Kitzberger C, Berger S, Schmohl K, Schwenk N, et al.
Mol Ther Oncolytics
. 2021 Dec;
23:432-446.
PMID: 34853814
Lipo-oligomers, post-functionalized with ligands to enhance targeting, represent promising new vehicles for the tumor-specific delivery of therapeutic genes such as the sodium iodide symporter (). Due to its iodide trapping...
5.
Koehler V, Keller P, Waldmann E, Schwenk N, Kitzberger C, Schmohl K, et al.
Endocrinol Diabetes Metab Case Rep
. 2021 Mar;
2021.
PMID: 33682680
Summary: Struma ovarii is a teratoma of the ovaries predominantly composed of thyroid tissue. Hyperthyroidism associated with struma ovarii is rare, occurring in approximately 8% of cases. Due to the...
6.
Schmohl K, Han Y, Tutter M, Schwenk N, Sarker R, Steiger K, et al.
Endocr Relat Cancer
. 2020 Oct;
27(12):685-697.
PMID: 33112795
Thyroid hormones are emerging as critical regulators of tumour growth and progression. To assess the contribution of thyroid hormone signalling via integrin αvβ3, expressed on many tumour cells, endothelial cells,...
7.
Tutter M, Schug C, Schmohl K, Urnauer S, Kitzberger C, Schwenk N, et al.
Mol Ther
. 2020 Oct;
29(2):788-803.
PMID: 33068779
The tropism of mesenchymal stem cells (MSCs) for tumors forms the basis for their use as delivery vehicles for the tumor-specific transport of therapeutic genes, such as the theranostic sodium...
8.
Tutter M, Schug C, Schmohl K, Urnauer S, Schwenk N, Petrini M, et al.
Theranostics
. 2020 Apr;
10(10):4490-4506.
PMID: 32292510
: The tumor homing characteristics of mesenchymal stem cells (MSCs) make them attractive vehicles for the tumor-specific delivery of therapeutic agents, such as the sodium iodide symporter (NIS). NIS is...
9.
Schmohl K, Mueller A, Dohmann M, Spellerberg R, Urnauer S, Schwenk N, et al.
Thyroid
. 2019 Dec;
29(12):1843-1857.
PMID: 31816265
Several clinical and experimental studies have implicated thyroid hormones in cancer progression. Cancer-relevant effects, including stimulation of tumor growth and new blood vessel formation by angiogenesis, are thought to be...
10.
Urnauer S, Schmohl K, Tutter M, Schug C, Schwenk N, Morys S, et al.
Gene Ther
. 2019 Jan;
26(3-4):93-108.
PMID: 30683895
Tumor heterogeneity, within and between tumors, may have severe implications for tumor therapy, especially for targeted gene therapy, where single-targeted approaches often result in limited efficacy and therapy resistance. Polymer-formulated...